OrsoBio Secures $67 Million in Funding for Next-Generation Obesity Treatments

Funding Round:
OrsoBio, an obesity-focused biotech startup backed by Eli Lilly, has raised $67 million in a Series B funding round.

Drug Portfolio:
The company is developing several weight loss medicines aimed at different drug targets than the GLP-1 therapies sold by Lilly and Novo Nordisk.

Clinical Progress:
Two of OrsoBio’s drugs are in Phase 2 testing for diabetes and metabolic dysfunction-associated steatohepatitis, while a third oral medication is expected to begin mid-stage testing soon.

Investment Purpose:
The funding will help advance OrsoBio’s portfolio of obesity drugs, focusing on combination approaches to address unmet needs in obesity and metabolic disorders.

Market Context:
The success of GLP-1 drugs has fueled billions of dollars in sales for Lilly and Novo Nordisk, but there remains a high unmet need for effective and safe oral therapies that can be used in combination with these agents.